In its recent 13F filing with the Securities & Exchange Commission, Kathmere Capital Management LLC disclosed a 0.7% reduction in its Merck & Co., Inc. stake during the second quarter. The firm sold 149 shares, leaving it with 19,802 total shares.
Subscribe
Stock Market
Kathmere Capital Management LLC Cuts Stake in Merck & Co., Inc. $MRK
Photo by Markets Daily
Key Takeaways:
- Kathmere Capital Management LLC reduced its Merck & Co. position.
- The reduction amounted to 0.7% in the second quarter of the year.
- The firm sold 149 shares, based on its latest 13F filing.
- After the sale, it now holds 19,802 shares.
- The data originates from TheMarketsDaily.
Kathmere’s Position and Share Sale
Kathmere Capital Management LLC has slightly trimmed its stake in Merck & Co., Inc. According to the company’s most recent 13F filing, the firm sold 149 shares during the second quarter, representing a decrease of 0.7%. As a result, Kathmere’s investment in the pharmaceutical giant now stands at 19,802 shares.
The SEC Filing
The information on this stake adjustment became public through a 13F filing with the Securities & Exchange Commission (SEC). These filings reveal changes in institutional investments and can provide insights into market strategies. Kathmere’s decision to sell a small number of shares underscores a measured approach rather than a wholesale exit from its Merck holdings.
Why This Matters
Investors and industry watchers monitor 13F filings to gauge the moves of institutional firms. Even a slight decrease, like Kathmere’s 0.7% cut in Merck holdings, can offer a glimpse into the firm’s evolving investment perspective. Merck, known for its broad pharmaceutical portfolio, often attracts attention in such filings, and Kathmere’s disclosure provides a snapshot of ongoing trends in the market.
